Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hookipa brings in €50mm via Series C

Executive Summary

Hookipa Biotech AG (immune activation therapies for cancer and infectious diseases) raised €50mm ($59.5mm) in an oversubscribed Series C financing round led by an undisclosed US blue chip public investment fund, which was joined by other first-time backers HBM Partners, Hillhouse Capital, Sirona Capital, and Gilead, and returning shareholders Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures, and BioMedPartners. The company will use the funds to move its Vaxwave-based HB101 cytomegalovirus vaccine into Phase II and for Phase I of a TheraT-based active immunization therapy in patients with head and neck squamous cell carcinoma. Additional money will help expand into other diseases such as prostate cancer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies